Incyte Corporation (INCY)

In the past six months, Incyte's stock price increased 12.32% since July 1, 2024, but declined 8% over the past six months as of April 1, 2025. The stock slipped 27.9% from its 52-week high. Incyte's shares closed down more than 7% after reporting its Q4 results. Incyte announced a pause in enrollment for a Phase 2 study and the discontinuation of INCB000547 development, leading to a $9.05 fall in the stock price. Incyte reached a settlement with Novartis Pharma AG regarding royalty payments for Jakafi. The US Court of Appeals reversed a preliminary injunction Incyte had obtained against Sun Pharmaceutical Industries. Incyte's PD-1 Blocker Zynyz received FDA approval for first-line anal cancer. The FDA extended the review period for ruxolitinib cream (Opzelura) for the treatment of children. Incyte announced the FDA approval of Monjuvi for patients with relapsed or refractory follicular lymphoma. Bill Meury was appointed as Chief Executive Officer, with Hervé Hoppenot retiring.

Significant demand seasonality for Incyte's products and services is generally not expected. Demand for biopharmaceutical products tends to be stable throughout the year, driven by patient needs and ongoing treatment regimens rather than seasonal fluctuations.

Incyte Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, operating within the Healthcare sector, specifically in the Biotechnology industry. Incyte's business centers on addressing serious unmet medical needs, primarily in hematology/oncology and inflammation and autoimmunity. Their portfolio includes marketed and co-marketed pharmaceutical products, including Jakafi, Opzelura, Pemazyre, Monjuvi/MINJUVI, Iclusig, Tabrecta, Olumiant, Zynyz, and Niktimvo.

Incyte Corporation is headquartered in Wilmington, Delaware, U.S., and has a global presence with locations across North America, Europe, and Asia. In North America, it has operations in Canada. In Europe, it has a headquarters in Switzerland and offices in several countries. In Asia, it has operations in Japan. It also has distribution agreements in Australia, New Zealand, and Singapore.

Incyte maintains a Medium Risk ESG Risk Rating of 23.7 as of May 23, 2025, with a Low controversy level. The company prioritizes transparency, providing an investor relations website and publishing a global responsibility report. However, the company's reputation has been impacted by an investigation by Levi & Korsinsky concerning possible violations of federal securities laws, ongoing patent disputes, and past legal issues.

Incyte Corporation has significant institutional ownership, with 1,367 institutional owners and shareholders holding approximately 96.97% of the stock. Major institutional owners include Baker Bros. Advisors Lp, Vanguard Group Inc, BlackRock, Inc., Dodge & Cox, State Street Corp, Aqr Capital Management Llc, and Geode Capital Management, Llc. Insider ownership is approximately 2.17% or 15.71%. Top direct holders among insiders include Dr. Pablo J. Cagnoni, Ms. Christiana Stamoulis, and Dr. Steven H. Stein.